RESEARCH USE ONLY
Incretin-Agonist Research Peptides
This topic hub covers a class of peptide research reagents that modulate incretin signaling pathways, with monographs on three key compounds: Retatrutide, Semaglutide, and Tirzepatide. Each entry details the compound's structure, mechanism of action on glucose homeostasis pathways, purity specifications, and relevant published research context. Researchers will find technical reference material for in vitro and in vivo laboratory investigations of incretin-mimetic physiology and receptor pharmacology.
In this topic
Incretin AgonistsRetatrutideRetatrutide (LY3437943) is a synthetic single-molecule triple agonist of the GIP, GLP-1 and glucagon receptors studied in metabolic research on obesity and type 2 diabetes.Incretin AgonistsCagrilintide (AM833) — a long-acting amylin analogueCagrilintide (AM833, NN0174-0833) is a rationally engineered, lipidated analogue of human amylin (IAPP) with a once-weekly activity profile. This monograph covers its chemistry, mechanism of calcitonin/AMY receptor activation, the preclinical and clinical research record, pharmacokinetics and analytical characterization. Prepared strictly for research use only (RUO).Incretin AgonistsLiraglutideLiraglutide (Victoza/Saxenda) is an acylated, once-daily GLP-1 analogue. Mechanism of action, pharmacokinetics, and key clinical data with verified sources.Incretin AgonistsSemaglutideSemaglutide is a long-acting acylated analogue of glucagon-like peptide-1, a GLP-1 receptor agonist that has been the subject of extensive preclinical and clinical research on glycaemic control and body-weight regulation. This overview is strictly scientific and reference in nature.Incretin AgonistsTirzepatideTirzepatide (LY3298176) is a synthetic peptide, a dual agonist of the GIP and GLP-1 receptors, studied in metabolic research of type 2 diabetes and obesity.